95 filings
Page 3 of 5
8-K
7bkip5cjj8mc03
13 Dec 21
Updated etavopivat Phase 1 trial results presented in two 2021 ASH Annual Meeting Oral Sessions
7:05am
8-K
y2j6hz dm2
12 Nov 21
Forma Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update
7:31am
8-K
1jvgl5xdyfvbod e71
7 Oct 21
Regulation FD Disclosure
7:32am
8-K
778sxg6a
13 Aug 21
Forma Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update
7:15am
S-3ASR
nzdj23fb422y
26 Jul 21
Automatic shelf registration
4:17pm
8-K
1qwiqtlbf x7
21 Jun 21
Submission of Matters to a Vote of Security Holders
5:04pm
8-K
jpyfxz3s2t trkjcs6
14 Jun 21
Forma Therapeutics Announces Appointment of Industry Veteran John E. Bishop, Ph.D., as Chief Technology Officer
7:12am
8-K
76x3zf3o ci20j
11 Jun 21
Forma Therapeutics Presents New Phase 1 Data on Etavopivat (formerly referred to as FT-4202) at 26th European Hematology Association Congress
7:12am
8-K
9hu3eeswt
14 May 21
Forma Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update
7:32am
DEFA14A
lqto99
21 Apr 21
Additional proxy soliciting materials
4:36pm
DEF 14A
o84p0 b2jw
21 Apr 21
Definitive proxy
4:33pm
S-8
av8 zn4lf1iraz3aul
30 Mar 21
Registration of securities for employees
5:09pm
8-K
quj86md
30 Mar 21
Forma Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
7:30am
10-K
o87v1f15
30 Mar 21
Annual report
12:00am
8-K
d7n84vw6swn0b1r580mv
24 Mar 21
Departure of Directors or Certain Officers
4:29pm
8-K
a6fpio56ddgh dzy
7 Jan 21
Departure of Directors or Certain Officers
4:35pm
424B4
opodqxbw4ok6q9ckni
11 Dec 20
Prospectus supplement with pricing info
4:09pm